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Physiological Response to Aerosol
Propellants
by Richard D. Stewart,* Paul E. Newton,* Edward D.
Baretta,* Anthony A. Herrmann,* Hubert V. Forster,*
and Ricardo J. Soto*
Acute exposures to isobutane, propane, F-12, and F-il in concentrations of250, 500, or 1000 ppm for
periods of 1 min to8 hr did not produce any untoward physiological effects as determined by the methods
employed which included serial EKG's and continuous monitoring of modified V5 by telemetry during
exposure. Repetitive exposures to these four propeilants were also without measurable untoward
physiological effect with the exception ofthe eight male subjects repetitively exposed to 1000 ppm, F-li,
who did show minor decrements in several ofthe cognitive tests. Ofparticular importance is the observa-
tion that none of the subjects showed any decrement in pulmonary function or alteration in cardiac
rhythm as the result ofexposure to concentrations ofthe gases or vapors far greater than encountered in
the normal useofaerosol products inthe home.
The "sniffing" of high concentrations of aerosol
propellants and organic solvent vapors to obtain a
"high" has resulted in the sudden death of ap-
proximately 300 teenagers, presumably due to
epinephrine sensitization of the heart and the de-
velopment of afatal cardiac arrhythmia (1-9). Since
there had been no reports of industrial workers de-
veloping arrhythmias related to exposure to these
same compounds at concentrations not exceeding
the Threshold Limit Values, concern for the safety
ofthe consumer using aerosol products in the home
did not become an issue until the reports ofZuskin
(10) and Speizer (11). In 1974 Zuskin and Bouhuys
suggested that aerosol propellants might be respon-
sible for the transient increase in airway resistance
observed after the use of hair sprays (10). Then
Speizer, Wegman, and Ramirez reported that brief
exposures to fluorocarbon-22 in the 300 ppm range
resulted in the development of severe palpitation in
pathology residents in Boston (11), and suggested
that exposure to "normal-use" concentrations of
aerosol propellants might pose health problems not
previously recognized.
The paucity of the human toxicological informa-
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tion regarding the health effects resulting from the
inhalation of four of the most widely used aerosol
propellants over the range of concentration en-
countered in both the home and industrial setting
prompted this investigation.
Experimental Procedure
Healthy adult male and female volunteers were
exposed in small groups in a controlled-
environment chamber to isobutane, propane,
fluorocarbon-12 (F-12, difluorodichloromethane),
or fluorocarbon-1 (F-11, fluorotrichloromethane)
concentrations ranging from those encountered in
the home to those permitted in the industrial setting.
First, a series of single exposures to 250, 500, and
1000 ppm to each ofthe propellants for periods of 1
min to 8 hr were conducted. As there were no un-
toward health effects, the subjects were then re-
peatedly exposed 5 days per week for 2 to 4 weeks
to 500 ppm isobutane, 1000 ppm propane, 1000 ppm
F-12, and 1000 ppm F-il. On several occasions,
subjects were exposed to mixtures ofthe gases and
solvents. The exposure schedule is presented in Ta-
bles 1-3.
These experiments were so designed that the ab-
sorption, excretion, and physiological effects ofthe
four propellant gases and solvent could be studied.
275Table 1. Exposure of human subjects to isobutane (Group 1).
Planned
isobutane
exposure, ppm
500
250
1000
500
500,
fluctuating
concentration
500, 10
repetitive
exposures
500, 10
repetitive
exposures
Subjects Duration of
Male Female exposure
4 4 1 min
4 4 2 min
4 4 10min
I 1 I hr
I 1 2hr
2 2 8hr
I I I hr
I 1 2 hr
2 2 8hr
I I I hr
I 1 2hr
2 2 8hr
I I I hr
I 1 2hr
2 2 8hr
I I I hr
I 1 2hr
2 2 8hr
I I I hr
I 1 2hr
2 2 8hr
I I I hr
I 1 2hr
2 2 8hr
I I I hr
I 1 2hr
2 2 8hr
I I I hr
I 1 2hr
2 2 8hr
I I I hr
I 1 2hr
2 2 8hr
I I I hr
I 1 2hr
2 2 8hr
4 4 8hr
4 4 8hr
4 4 8hr
Meanconcentration, I hr
10 repetitive 2 hr
exposures: 8 hr
Exposure, ppm
(mean S.D.)
514.4
506.3
504.2 15
245.9±7.2
245.7 19
244.5 23.6
1008.2 28.6
1005.7 26.9
1000.1 23.6
499.9 35
488.8 15
493.2 19.7
388.6 ± 91.9
649.8 ± 200
530.9 ± 258.8
509.4 ± 14.8
509.5 ± 21.2
506.6 ± 23.8
500.1 ± 58.1
486.2 ± 20.2
488.8 ± 33.0
498.9±9.4
505.2 ± 22.9
503.4±25.9
508.6 ± 29.1
513.0 ± 16.6
501.7 ± 31.6
504.5 ± 24.7
497.7 ± 16.3
502.6 ± 19.5
488.4 ± 30.6
497.1 ± 22.4
503.8 ± 28.2
492.6 ± 29.6
504.1 ± 23.6
504.2 ± 29.6
498.5 ± 26.7
506.9 ± 22.6
495.9 ± 29.9
500.4
501.8
501.2
Special emphasis was placed on monitoring cardiac
and pulmonary performance.
Subjects
A group of 43 male and 32 female subjects was
selected from the Caucasian, middle-class Mil-
waukee population. Of these, 24 were college stu-
dents, nine were housewives, five were nurses, and
two were physicians. The investigation was per-
formed with strict adherence to the ethical and
technical requirements for human inhalation ex-
perimentation previously detailed (12, 13). This in-
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Table 2. Exposure of human subjects to propane (Group II).
Pannedpropane Subjects Durationof Exposure, ppm
exposure, ppm Male Female exposure (mean ± S.D.)
1000 4 4 1 min 995.9
250
500
500,
fluctuating
concentration
4 4 2 min
4 4 10 min
I I I hr
I 1 2 hr
2 2 8 hr
1 1 1hr
1 1 2 hr
2 2 8 hr
2 2 8 hr
1002.5
981.8
284.1 ± 37
262.1 ± 20.5
255.5 ± 27.3
506.5 ± 13.4
502.1 ± 31.4
504.1 ± 24.9
496.8 ± 140.7
1000, 9 2 2 8 hr 1005.9 ± 140.1
repetitive 2 2 8 hr 992.9 ± 215.7
exposures 2 2 8 hr 1001.7 ± 44.5
2 2 8 hr 994.3±69.5
2 2 8 hr 1006.4±44
2 2 8 hr 999.3 ± 61.6
2 2 8 hr 91.8±54.6b
2 2 8 hr 1029.9 ± 38.7b
2 2 8 hr 1014.5±37.5
b Combined with isobutane(see Group II experiments, Table 3).
Table 3. Exposure of human subjects to isobutane-propane
mixtures (Group III).
Planned
exposure Subjects Duration of
Isobutane exposure, Exposure, ppm
Propane Male Female hr (mean ± S.D.)
82.5%/17.5% 1 1 1 Isobutane: 461.5 ± 74.5
Propane: 106.8 ± 15.0
82.5%/17.5% 1 1 1 Isobutane: 536.5 ± 38.1
Propane: 77.4± 7.4
1 1 2 Isobutane: 482.6 ± 74.2
Propane: 102.0 ± 10.8
2 2 8 Isobutane: 501.8 ± 82.0
Propane: 100.2 ± 18.4
89%o/11% 2 2 8 Propane: 961.8 ± 54.6
Isobutane: 110.7± 6.2
87.5%/12.5% 2 2 8 Propane: 1029.9 ± 38.7
Isobutane: 142.7 ± 5.7
cluded obtaining the informed consent ofeach sub-
ject after the nature ofthe procedure had been fully
explained.
The ages of the male subjects ranged from 18 to
46 years, height from 177.8 to 187.2 cm, and weight
from 70.0 to 81.5 kg. The ages ofthe females ranged
from 18 to 35 years, theirheight from 155 to 174 cm,
and their weight from 57.2 to 72.9 kg.
All subjects were cautioned to abstain from the
use ofdrugs and to limit their use ofalcohol to very
moderate amounts. Subjects who were smokers
were not allowed to smoke during their stay in the
controlled-environment chamber. Subjects who
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fluorotrichloromethane vapor.
Exposure, ppm
Planned
group Durationof (%)
exposure, ppm Subjects exposure,hr Mean S.D. C.V.a
Group I: 9 males inChamberNo. 1
2 males
3 males
3 males
2 males
3 males
3 males
3 males
3 males
3 males
3 males
3 males
3 males
3 males
3 males
3 males
2 males
3 males
3 males
2 males
3 males
3 males
2 males
3 males
2 males
2 males
8
8
2
1
8
2
1
0
495.8
497.9
489.8
0
8 997.0
2 1001.5
1 1016.7
8 0
2
1
8 250.2
2 246.1
1 257.2
8 246.9
2 241.1
1 239.6
8 512.8
2 507.5
1 527.6
8 0
2
1
15.3 3.09
10.0 2.03
27.1 5.53
31.8 3.19
28.1 2.80
24.1 2.37
7.8
9.0
5.5
10.4
12.8
3.1
15.5
10.9
0.3
3.11
3.68
2.14
4.21
5.30
1.27
3.02
2.15
.06
Group II: 8 males in Chamber No. 2
8 males 8 0
8males 8 0
8males 8 0
8 males 8 250.1
8 males 8 499.9
8 males 8 1000.3
7 males 8 999.5
8 males 8 1001.1
8 males 8 999.1
8 males 8 999.7
8males 8 991.1
8 males 8 1001.0
8 males 8 1000.8
8 males 8 994.4
8 males 8 996.0
8 males 8 996.8
8 males 8 1001.3
8 males 8 1000.7
8 males 8 1000.0
8 males 8 998.7
8 males 8 999.9
8 males 8 273.7
8 males 8 1000.6
8 males 8 1000.2
1 male 1 1014.3
1 male 1 1000.8
1 male 1 1003.5
8 males 2 1016.4
15.3
13.7
42.6
31.6
27.7
41.5
20.7
61.1
22.1
27.8
20.6
23.8
23.3
18.6
24.1
23.3
17.4
12.6
146.1
16.8
20.2
30.7
15.6
24.6
16.7
6.13
2.75
4.26
3.16
2.77
4.15
2.07
6.16
2.30
2.78
2.08
2.39
2.34
1.85
2.50
2.33
1.74
1.26
53.69
1.68
2.02
3.03
1.55
2.45
1.65
Table4continued
Exposure, ppm
Planned
group Durationof (%)
exposure, ppm Subjects exposure,hr Mean S.D. C.V.a
I male 1 1015.1 19.1 1.88
0 8 males 8 0
0 8males 8 0
Group III: 10females in Chamber No. 1
500 2 females 1 502.9 4.48 0.89
4females 2 500.7 5.59 1.12
4females 8 501.5 7.84 1.56
1000 2 females 1 1016.8 19.59 1.93
4females 2 1009.9 18.44 1.82
4females 8 1012.59 16.00 1.58
250 2 females 1 253.81 3.67 1.45
4females 2 253.11 4.21 1.66
4females 8 254.36 18.04 7.09
Group IV: 4 males and 4females in Chamber No. 2
1000 1 male 1 978.8 58.9 6.02
1 female
1000 I male 2 1011.5 27.9 2.76
1 female
1000 2 males 8 1004.8 38.8 3.86
2females
Group V: 7 males and 4females in Chamber No. 2
1000 8 males 10 987.1 15.7 1.59
1000 5 males 1 983.0 11.3 1.15
2 females
5 males 1 1008.1 2.9 0.29
6 males 2 1001.0 0.0
2 females
1000 5 males 10 1001.8 5.1 0.51
1000 4males 10 1021.8 11.9 1.17
2 females
1000 5 males 2 1015.2 1.6 .16
a C.V. = coefficient ofvariation.
underwent behavioral testing were asked to refrain
from consuming any caffeine prior to the end of
each day's study (1 hr post-exposure).
Exposure Schedule
Tables 1-5 list the exposure sequences, the
number of subjects, the gas or vapor concentration
investigated, and the duration of each exposure.
Exposure Chamber
The experiments were conducted in a
controlled-environment chamber having a 20 ft x 20
ft x 8 ft testing room with an attached shielded
room and an attached toilet facility. The air flow
through the suite of rooms to the exhaust was ap-
proximately 1500 ft3/min, which created a slight
negative pressure within the chamber. The ambient
temperature within the chamber was maintained at
October 1978
0
500
0
1000
0
250
250
(F- l)
Combined with
(F-12), 500
0
0
0
0
250
500
1000
1000
1000
1000
1000
1000
1000
1000
1000
1000
1000
1000
1000
1000
1000
1000
Fluctuating
1000
1000
1000
277subjects to dichlorodifluoromethane
Planned Duration of Exposure, ppm
Group exposure, ppm Subjects exposure, hr Mean S.D. C.V.
Group I: 11 males in Chamber No. 2
0 11 males
0 4 males
4 males
250
1000
1000
8
6
2
8
2
1
4 males
4 males
3 males
4 males
4 males
3 males
4 males
4 males
3 males
4 males
3 males
2 males
4 males
3 males
3 males
500
0
Group II: 8 males in Chamber No. 2
0 8 males
0 8 males
0 8 males
1000 8 males
1000 8 males
1000 8 males
1000 8 males
1000 8 males
1000 8 males
1000 8 males
1000 8 males
1000 7 males
1000 8 males
1000 8 males
1000 8 males
1000 8 males
1000 8 males
1000 8 males
1000 8 males
1000 4 males
1000 4 males
1000 8 males
Fluctuating 8 males
0 8 males
0 8 males
Group III: 10 females in Chamber No. 1
0 3 females
4 females
4 females
0 3 females
4 females
4 females
500
0
0
0
246.7
250.9
246.3
8 1012.6
2 1013.6
1 1021.3
8 1016.4
2 1010.0
1 1036.5
8 498.2
2 511.5
1 538.5
8
2
1
0
0
0
8 0
8 0
8 0
8 1000.8
8 1005.37
8 1001.1
8 999.1
8 1000.0
8 1000.6
8 1004.7
8 999.6
8 1000.7
8 1000.4
8 1000.2
8 1006.7
8 999.6
8 1000.9
8 999.7
8 999.1
2 1000.2
1 1002.5
8 999.4
8 284.7
8 0
8 0
2
8
2
8
2
8
2
8
3 females
4 females
4 females
2 females
4 females
4 females
1000
0
0
0
0
0
0
502.3
503.7
501.5
1013.2
1012.5
1008.4
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0
0
0
9.5
4.2
8.9
44.1
46.9
29.8
39.7
28.8
27.8
10.5
12.7
48.0
0
0
0
30.6
19.5
24.1
21.5
16.6
62.2
17.6
44.5
17.6
18.9
20.9
18.9
23.0
19.5
16.6
16.5
21.5
18.5
21.7
139.9
0
0
0
0
0
0
8.76
7.56
8.53
17.96
19.74
20.12
0
0
0
3.85
1.67
3.61
4.35
4.63
2.92
3.91
2.85
2.68
2.10
2.48
8.91
0
0
0
3.06
1.94
2.4
2.15
1.66
6.22
1.76
4.45
1.76
1.89
2.08
1.88
2.30
1.95
1.66
1.65
2.15
1.85
2.17
49.14
0
0
0
0
0
0
1.74
1.50
1.70
1.77
1.95
1.99.
Table S. Exposure of human,. vapor.
278Table 5 continued
Planned Duration of Exposure, ppm
Group exposure, ppm Subjects exposure, hr Mean S.D. C.V.
0 2 females 1 0 0 0
4 females 2 0 0 0
4 females 8 0 0 0
250 3 females 1 250.4 2.49 0.99
4 females 2 251.1 3.00 1.19
3 females 8 250.6 2.80 1.12
0 2 females 1 0 0 0
4 females 2 0 0 0
4 femates 8 0 0 0
Group IV: 4 males and 4 females in Chamber No. 2
500 1 male 1 508.6 16.2 3.18
1 female
500 1 male 2 500.3 21.2 4.23
1 female
500 2 males 8 501.5 18.2 3.63
2 females
Group V: 9 males in Chamber No. 2
1000 3 males 1 952.0 8.0 0.8
3 males 2 963.3 15.6 1.62
3 males 10 986.6 24.0 2.43
72-74°F, while the relative humidity ranged be-
tween 45 and 55%.
The propellant gases or vapor were mixed with
the air supplying the chamber, entering through four
diffusers in the ceiling ofthe testing room. To obtain
the desired concentration, the gases were metered
from a cylinder into the return air duct of the air
conditioner while the liquid F-11 was pumped at a
constant rate into a flask through which a stream of
air swept the vapor into the return air duct.
Chemicals
The isobutane used in these experiments had a
boiling point of 10.89°F, a vapor pressure of 3733
mm Hg at (100°F), a vapor density of2.068 at (60°F
and 24.7 psig), and a specific gravity of 0.563 at
(60/600F).
The propane had a boiling point of -44.480F, a
vapor pressure of 6612 mm Hg, a vapor density of
1.549, and a specific gravity of0.509 (60/60°F).
The F-12 and F- 11 used in these experiments was
shown by infrared analysis to be 99.9% pure.
Analysis of Exposure Chamber Atmosphere
Two independent systems were used to monitor
the chamber atmosphere. In both cases, air was
withdrawn from the chamber through a 1/4 in I.D.
polyethylene tube at approximately 71/min, through
or past the analytical device, to a small diaphragm
pump which discharged back into the chamber.
The concentration of the gases or vapor in the
chamber atmosphere was recorded continuously by
a Wilks Miran-I infrared spectrometer equipped
with a gas cell of 20 m path length. The following
infrared absorbances were measured: 3.4 , for
isobutane and propane, 9.1 u for F-12, and 11.9 g
for F-1. The voltage output was connected in a
strip-chart recorder, and a voltage proportional to
the pen position of that recorder was conducted to
the analog-to-digital input of a PDP-12 (DEC) com-
puter. The computer sampled pen position voltage
each second, averaged those voltages every 30 sec,
recorded the average on magnetic tape, and used
the average to write on a CRT the concentration
over that 30-sec interval and the cumulative or
time-weighted average concentration since the be-
ginning of the exposure session.
Gas chromatography (GC) was the second
method of chamber air analysis. The Varian Aero-
graph Series 2700 GC was used. An automatic de-
vice injected a sample of air into the GC every 170
sec. Output of the GC was connected to a strip-
chart recorder. After each exposure ended, a calib-
ration curve for the GC values was established with
the computer using regression analysis on the stan-
dards that had been analyzed during the day. With
that equation, peak-height values read manually
were transformed into concentrations which were
then used to calculate time-weighted averages and
standard deviations for exposure increments to
compare with the values obtained using the infrared
spectrometer. Concentrations found by the two
October 1978 279methods were in agreement throughout the study.
Standards were prepared by filling saran bags
with room air pumped in sequence through a char-
coal column, a wet test meter, a Drierite column,
and a type N all-service gas mask canister. After
filling a bag with aknown amountofclean, dry air, a
known volume ofF- 1, F-12, isobutane, or propane
was injected into the bag. Calibration of analytical
devices was accomplished by attaching the saran
bag standard to the sampling probe within the
chamber. At least three standards were analyzed
prior to allowing subjects to enter the chambereach
day and then standards were analyzed at approxi-
mately 1 hr intervals throughout the day.
Clinical Testing
Prior to exposure, each subject was given a com-
prehensive medical examination which included a
complete history and physical examination and the
laboratory studies listed below. None of the sub-
jects was taking medication. Periodic urine screen
for drugs confirmed none ofthe subjects was taking
illicit drugs.
All exposures of 1 hr or more duration were con-
ducted by usi.ig a double-blind format.
Prior to commencing the actual exposures, the
subjects underwent a training program in the
controlled environmental chamber during which
time they became accustomed to the chamber set-
ting and the testing procedures.
Each subject was given a repeat physical exami-
nation prior to each exposure. At this time each
completed a "symptom check list." This form had
designated spaces for noting the presence of
headache, nausea, dizziness, abdominal pain, eye,
nose, throat irritation, or other subjective
symptoms. Each subject reviewed this list of
symptoms immediately upon entering the chamber
and each hour during and for 5 hr following each
exposure. The adjectives, "mild, moderate, and
strong," appeared on the sheet as cue words, and
the phrase, "only abnormalities recorded," was
prominently typed at the bottom. The home tele-
phone numbers of each of the Department physi-
cians appeared on the form and the subjects were
told to phone should they become ill while away
from the laboratory.
Prior to and following the exposures, the follow-
ing laboratory determinations were made: complete
blood count, urinalysis, alkaline phosphatase,
SGOT, LDH, bilirubin, blood sugar, calcium,
phosphorus, BUN, blood and alveolar breath sam-
ples for propellant analysis. A 24 hr urinary fluoride
excretion determination was made on each subject
exposed to F-12 or F-il. The following studies
completed the pre-exposure evaluation: comput-
erized spirometry, 12-lead EKG, and a modified V5
EKG rhythm strip by telemetry.
During each exposure in the environmental
chamber the subjects were under continual visual
surveillance by medical personnel and all important
chamber activities were videotaped by closed-
circuit TV. Modified V5 was monitored continu-
ously by telemetry. A hard copy of this EKG was
obtained after 30 min ofexposure and hourly there-
after. When a change in cardiac rhythm was ob-
served, a hard copy rhythm strip was obtained.
Immediately after entering the environmental
chamber, each subject performed a modified Rom-
berg test followed by a heel-to-toe test. These tests
were first performed with eyes open and then re-
peated with closed eyes. Then, each subject com-
pleted his subjective symptom check list as previ-
ously discussed. Each subject repeated the mod-
ified Romberg test and the heel-to-toe test 5 min
before leaving the exposure chamber.
Subjects exposed for 2 hr or more performed the
following during the final 40 min ofexposure: com-
puterized spirometry measurement, which included
the maximum mid-expiratory flow rate, Flanagan
coordination test, Marquette time estimation test
(14) and random number inspection test. During the
repetitive studies the above tests were performed
twice a week during the final 2 hr of exposure.
During the repetitive exposures to F-12 and F-Il
systolic time interval measurements were made
before exposure and immediately following 8 hr of
exposure (15). During the repetitive exposures to
isobutane and propane the second systolic time
interval measurement was made during the final
hour of exposure.
The spontaneous EEG and VER of selected sub-
jects were recorded four times each Monday,
Wednesday, and Friday during the repetitive expo-
sures (16-18). Recordings were made once during
the first hour and three times between the fifth and
seventh hours of exposure. All recordings were
obtained while the subjects were seated in a com-
fortable upholstered chair in the shielded room in
which the hydrocarbon concentrations were identi-
cal to those in the controlled environmental
chamber.
Alveolarbreath samples were obtaineddailyfrom
each subject prior to entry into the environmental
chamber, and serially following each exposure.
These samples were each collected in 5-liter saran
bags by using the technique previously described in
detail (19).
Blood samples for propellant analysis were ob-
tained from an antecubital vein ofeach subject pre-
exposure, 15 min pre-exit, and 15 min post-
Environmental Health Perspectives 280exposure in Vacutainer tubes with edetic acid an-
ticoagulant. The pre-exit sample was obtained by
having the exposed subject stick his arm through an
armport in the chamber wall into the uncontam-
inated adjacent laboratory.
Analysis of Ambient Air, Expired Breath
and Blood
Air and breath samples for propellant analysis
were injected directly onto a Porapak Q column ofa
Varian Aerograph Series 2700 gas chromatograph
equipped with ahydrogen flame ionization detector.
A headspace sampling technique was utilized for
measuring the concentration of the propellants in
the blood. The details of the analytical procedures
used have been presented elsewhere (16-19).
Medical Surveillance After Exposure
A resting 12-lead electrocardiogram was obtained
15-30 min post-exposure. All of the pre-exposure
clinical studies were repeated on a weekly basis
during the period ofexposure. On the day following
the last exposure ofany sequence, each subject was
given a repeat comprehensive medical examination.
This included a complete history and physical
examination with the following laboratory studies:
complete blood count, urinalysis, complete panel of
clinical chemistries (23 values plus 2 calculated),
computerized spirometry, and a 12-lead electrocar-
diogram (EKG).
Those subjects who had been exposed repeti-
tively underwent the standard 2-day ACTH stimu-
lation test to assess the adrenal gland's ability to
respond to stress. Then the health of each subject
was monitored for one year by the investigators.
Results
Analysis ofExposure Chamber Atmosphere
The daily time-weighted average concentrations
of the propellants in the controlled-environment
chamber for each of the exposure situations are
found in Tables 1-5. The actual concentrations were
within a few percent of those desired.
Medical Surveillance
No untoward subjective symptoms or objective
signs ofillness were noted during exposure or in the
surveillance period which followed each exposure.
Pre- and post-exposure comprehensive medical
examinations revealed that all subjects remained in
good health during the study. All of the clinical
hematologies and chemistries remained within the
limits of normal. The comprehensive history and
physical forms used in the study and a listing ofthe
clinical laboratory values obtained are available for
review in the three project reports (16-18).
Effects of Exposure on the Heart
None of the subjects experienced any untoward
signs or symptoms referrable to his heart during ex-
posure or in the post-exposure period of surveil-
lance. No change from the pre-exposure control
EKG tracing was observed in the post-exposure
standard 12-lead EKGs or in modified lead V5 mon-
itored continuously during exposure by telemetry.
With one exception, none of the subjects had an
arrhythmia during exposure.
One subject in the acute series of exposures to
F-12 was observed to be experiencing premature
ventricular contractions at a rate of 1-2/min prior to
commencing a 1 hr exposure to 1000 ppm F-12. This
subject was exposed for 1 hr during which time his
telemetered EKG was continuously recorded. The
rate at which the premature ventricular contractions
occurred was unaltered by the exposure and con-
tinued unchanged for 3 hr post-exposure. The fol-
lowing day no premature ventricular contractions
were observed during two, 30 min monitoring
periods. The subject was monitored for 4 hr one
week later, and no premature ventricular contrac-
tions were observed.
The systolic time interval measurements were
unaltered by the exposures to the four propellants.
The normal diurnal variation was observed. The
pre-ejection period (PEP), ejection time (LVET),
the PEP/LVET ratio, and total electromechanical
systole (the Q-A2 interval) remained normal and
unchanged. Table 6 presents the data for those
subjects repetitively exposed to F-1 (16).
Pulmonary Function Studies
The functional integrity ofthe pulmonary airways
as monitored by the pulmonary function tests did
not appear to be affected by either the acute or the
repetitive series of exposures. A summary of the
spirometric data are listed in Tables 7-10. No trends
or consistent changes were noted.
Neurological Studies
No neurological abnormalities occurred during
the observation period. The modified Romberg test
and the heel-to-toe remained normal. The routine
neurological test was unaltered by the exposures
(16-18).
October 1978 281Table 6. Systolic time intervals of eight subjects who were repetitively exposed to F-1l, 1000 PPM, 8 hr/day.
Mean times and standard deviations, msec
F-li Electromechanical Left ventricular
concentration, time period ejection time Pre-ejection period
Exposure ppm QS2 (LVET) (PEP) PEP/LVET
AM 0 542.64 ± 14.99 436.55 14.24 103.67 21.69 0.23 ± 0.06
(control)
AM 543.90 ± 20.71 438.09 ± 14.94 109.56 + 20.12 0.25 ± 0.05
0
PM (control) 534.82± 19.12 419.46 12.67 115.35±21.73 0.28±0.06
AM 543.01 ± 13.53 438.71 ± 15.24 104.24 16.45 0.23 ± 0.05
Day 19 1000
PM 537.70 ± 14.34 423.33 ± 14.56 114.37 16.90 0.26 ± 0.05
AM 545.20 14.48 441.29 14.68 103.94 25.15 0.23 ± 0.07
Day 20 1000
PM 539.68 13.03 428.16 15.28 111.52 21.15 0.26 ± 0.06
AM Fluctuating 548.76 14.38 438.56 13.18 110.20 ± 22.44 0.25 ± 0.06
Day 22 (mean 275)
PM 536.97 10.82 427.02 19.24 109.95 ± 21.98 0.25 ± 0.07
AM 543.19 16.61 435.84 17.53 107.23 ± 25.67 0.25 ± 0.07
Day 23 1000
PM 537.73 11.20 424.97 15.12 112.75 ± 17.66 0.26± 0.05
AM 547.40 ± 21.13 441.49 ± 19.28 105.90 ± 25.48 0.23 ± 0.06
Day 24 1000
PM 531.15± 16.52 427.21± 13.76 103.94±23.48 0.24±0.06
Table 7. Pulmonary function after 5 hrexposure to isobutane.a
FVC, FEy, 0 PEFR, MMEF,
Condition 1. BTPS FVC 1./sec 1./sec
Repetitive exposure, 500 ppm, n = 4
Control 4.30 ± 0.97 87.58 ± 3.49 9.42 ± 2.56 4.74 ± 1.24
Ist day, 1st wk 4.44 ± 1.23 85.58 ± 7.67 8.84 ± 2.46 4.54 ± 0.49
3rd day, Ist wk 4.27 ± 1.29 88.65 ± 7.42 8.65 ± 2.71 4.69 ± 0.29
2nd day, 2nd wk 4.32 ± 1.15 86.8 + 6.29 8.64 ± 2.48 4.44 ± 0.16
5th day, 2nd wk 4.53 ± 1.16 83.85 ± 4.88 8.44 ± 2.27 4.49 ± 0.37
Single exposure, 1000 ppm, n = 3
Control 4.14 ± 1.01 85.63 ± 5.53 8.67 ± 1.88 4.20 ± 0.30
Single exposure 4.15 ± 0.98 85.17 ± 4.38 8.58 1.72 4.13 ± 0.65
a Pulmonary function: FVC = maximum volume ofair exhaled after a maximum inspiration; FEV,/FVC = percent ofFVC exhaled
in 1 sec; PEFR = maximum rate of air flow during FVC maneuver; MMEF = maximum rate of air flow at midpoint of FVC.
Table 8. Pulmonary function after5 hrexposureto propane.a
FVC, FEy, % PEFR, MMEF,
Condition 1. BTPS FVC 1./sec 1./sec
Repetitive exposures, 1000 ppm, n = 4
Control 5.18 1.30 82.9 ± 4.26 10.62 ± 2.36 5.51 ± 1.82
1st day, 1st wk 5.18 + 1.74 82.93 ± 3.36 10.26 ± 3.58 5.72 ± 3.13
5th day, 1st wk 5.31 1.80 83.15 ± 1.70 10.53 ± 3.50 5.66 ± 2.62
4th day, 2nd wk 5.10 1.37 83.86 ± 2.76 10.48 ± 2.62 5.34 ± 1.57
5th day, 2nd wk 5.16 1.32 83.91 + 3.34 10.58±2.56 5.58 ± 1.83
Single exposure, 1000 ppm, n = 4
Control 5.26 ± 1.47 85.26 + 2.95 11.25 + 2.24 5.46 ± 1.37
Single exposure 5.22 ± 1.37 84.13 + 4.04 10.72 + 2.38 5.30 ± 1.76
aPulmonary function: FVC = maximum volume ofair exhaled after a maximum inspiration; FEV1/FVC = percent ofFVC exhaled
in 1 sec; PEFR = maximum rate of air flow during FVC maneuver; MMEF = maximum rate of air flow at midpoint of FVC.
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fluorocarbon-1l.a
FVC, FEV, Zo PEFR, MMEF,
Condition 1. BTPS FVC 1./sec 1./sec
Repetitive exposure F-ll, 1000ppm,n = 8
Control 5.94 80.6 11.41 4.92
0.6 5.6 0.7 0.4
4thday, lstwk 5.76 82.4 11.47 5.09
0.5 9.1 0.5 0.7
6.12 81.1 11.73 5.01
4thday, 2nd wk. 0.7 6.2 0.3 0.6
4thday, 3rd wk 6.26 81.1 12.02 5.20
0.4 4.1 0.6 0.6
4thday, 4th wk 5.81 81.1 11.41 5.10
0.7 5.1 0.4 0.5
Single exposure F-ll, 1000ppm,n = 7
Control 4.76 76.1 9.08 4.32
0.4 9.1 0.5 0.7
Single exposure 4.87 74.5 9.81 4.45
0.7 11.0 0.3 1.1
a Pulmonary function: FVC = maximum volume ofair exhaled
after a maximum inspiration; FEV,/FVC = per cent of FVC
exhaled in 1 sec; PEFR = maximum rate of air flow during FVC
maneuver; MMEF = maximum rate of air flow at midpoint of
FVC.
Electroencephalography
No significant alterations occurred in the EEGs
of any of the subjects under any of the exposure
conditions. Time constraints precluded the obtain-
ing of a complete EEG, thus limiting the value of
these data. Actual EEG tracings are reproduced in
the three project reports (16-18).
Visual Evoked Response
The visual evoked responses recorded during the
single exposures were remarkedly reproducible and
did not indicate any changes attributable to acute
exposure to the four propellants at the concentra-
tions studied.
During the repetitive exposures the only signifi-
cant VER changes observed occurred during the
second week of exposure to 500 ppm isobutane
During this period a definite reduction in wave
amplitude was observed. Representative VER
tracings are presented in the three project reports
(16-18).
Cognitive Tests
With the exception of F-Il, exposure to the pro-
pellants or to mixtures ofpropellants did not result
in cognitive test performance decrements. The eight
male subjects repetitively exposed to F-lI did show
statistically significant decrements in cognitive test
performance (16).
The mean test performances under control and
exposure conditions were plotted for each control
and exposure day. Then alinearregression line with
75% confidence limits was drawn through the 0 ppm
data. Afteradjustingforthe trend through the 0ppm
data, t-tests were performed to determine ifthe ex-
posure data were significantly different from the re-
gression line. The results of these t-tests are pre-
sented in both graphic and tabular form in the three
project reports (16-18).
Sporadic individual improvement ordecrement in
test performance was observed from time to time.
However, in the absence ofa consistent decrement
in test performance or a dose-related response, the
test results are interpreted as showing no effect of
exposure at the concentrations studied.
ACTH Stimulation Test
Following the repetitive exposures the subjects
had normal 24 hr urinary 17-ketosteroid and 17-
hydroxyketosteroid excretion. The subjects given
an 8 hr ACTH stimulation test (40 units) on two
successive days showed anormal response (16-18).
Table 10. Puhnonary functionafter6hrexposure tofluorocarbon-12.a
FVC, FEV, 0 PEFR, MMEF,
Condition 1. BTPS FVC 1./sec 1./sec
Repetitive exposure F-12, 1,000 ppm, n = 8
Control 5.84 0.6 80.6 5.6 11.41±+0.7 4.92 0.4
4th day, Ist wk 5.89 0.5 82.6 6.1 11.51 0.5 4.97 0.7
4th day, 2nd wk 5.85 0.7 83.2 6.2 11.27 0.3 5.13 0.6
4th day, 3rd wk 5.85 ±0.4 82.5 ±5.1 11.46 0.6 4.92 ±0.6
4th day, 4th wk 5.62 0.5 84.9 4.1 11.42 0.4 5.05 0.5
Single exposure F-12, 1000ppmn = 7 males
Control 4.76 ± 0.4 76.1 ± 9.1 9.08 ± 0.5 4.32 ± 0.7
Single exposure 4.77 ± 0.7 78.5 ± 10.6 9.72 ± 0.6 4.55 ± 0.8
Single exposure F-12, 1000 ppm, n = 4 females
Control 4.10 ± 0.7 78.2 ± 6.1 8.93 ± 0.5 5.10 ± 0.7
Single exposure 4.00± 0.5 76.7 ± 9.2 9.10 ± 0.6 4.85 ± 0.6
a Pulmonary function: FVC = maximum volume ofair exhaled after a maximum inspiration; FEV,/FVC = percent ofFVC exhaled
in I sec; PEFR = maximum rate of air flow during FVC maneuver, MMEF = maximum rate ofair flow at midpoint of FVC.
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Isobutane, propane, F-12, and F-II were readily
detected in the expired breath of each of the sub-
jects following exposure to the concentrations in-
vestigated. These post-exposure breath data are
detailed in the project reports (16-18). Examination
of these breath data reveals that a predictable
excretion pattern exists for each of the exposure
conditions studied, and that the following factors
influence the concentration of the propellant in the
breath: concentration of inspired gas or vapor, du-
ration of exposure, and length of time post-
exposure that the breath sample is obtained. From
the data presented a "family" of post-exposure
breath excretion curves useful in estimating the
magnitude ofexposure can be constructed (16-18).
Blood Analysis
Isobutane, propane, F-12, and F-II were present
in detectable concentrations in the blood of the
subjects exposed under the conditions of this ex-
periment. However, the sensitivity of the analytic
method severely limits the usefulness of this tech-
nique for monitoring the body burden except in the
early post-exposure interval (16-18).
Comments
Acute exposures to isobutane, propane, F-12,
and F-II in concentrations of250, 500, or 1000 ppm
for periods of 1 min to 8 hr did not produce any
untoward physiological effects as monitored by the
methods employed. Repetitive exposures to these
four propellants were also without measurable un-
toward physiological effect with the exception of
the eight male subjects repetitively exposed to 1000
ppm F-I1, who did show minor decrements in sev-
eral of the cognitive tests. Should these observa-
tions prove representative of the general popula-
tion, a significant percentage of persons identically
exposed to the upper industrial limits ofF-I 1 would
be expected to show similar decrements in cognitive
function. Fortunately, the magnitude of the decre-
ments observed was minute and transient. In the
opinion ofthe investigators, these small decrements
occurring during repetitive exposures were spurious
in that similar decrements were not observed in the
subjects acutely exposed to the same concentration
for equal periods of time. Further research on the
effect of F-lI on cognitive function is merited.
Of particular importance is the observation that
none of the subjects showed any decrement in pul-
monary function or alteration in cardiac rhythm as
the result ofexposure to concentrations ofthe gases
or vapors far higher and of much greater duration
than would occur in the normal use of commercial
aerosols in the home. Thus, it would seem that ex-
posure to the current Threshold Limit Value (TLV)
for American industry does not have the potential to
adversely affect a normal heart or lungs.
These extended observations fail to corroborate
the speculation of Speizer et al., who performed
less comprehensive studies and suggested that brief
exposures to fluorocarbons could result in the de-
velopment of cardiac arrhythmias (11).
The analysis ofexpired breath for isobutane, pro-
pane, F-12, or F-Il in the early post-exposure
period provides a feasible diagnostic test of expo-
sure. The use of gas chromatography permits the
detection ofthe gases or vapors for at least 5 hrafter
exposure to the TLV. Serial breath analyses fol-
lowing exposure provides a means to estimate the
magnitude of exposure since the amount of a gas
present following exposure is determined by the in-
spired concentration, the duration ofexposure, and
the elapsed time following exposure.
Summary
Acute exposures to isobutane, propane, F-12,
and F- 11 in concentrations of250, 500, or 1000 ppm
for periods of 1 min to 8 hr did not produce any
untoward physiological effects as determined by the
methods employed which included serial EKGs and
continuous monitoring of modified V5 by telemetry
during exposure. Repetitive exposures to these four
propellants were also without measurable untoward
physiological effect with the exception of the eight
male subjects repetitively exposed to 1000 ppm
F-11, who did show minor decrements in several of
the cognitive tests. Of particular importance is the
observation that none of the subjects showed any
decrement in pulmonary function or alteration in
cardiac rhythm as the result ofexposure to concen-
trations of the gases or vapors far greater than en-
countered in the normal use of aerosol products in
the home.
This investigation was supported in part from funds collected
by the Ad Hoc Aerosol Committee, representatives of major
trade associations, and industrial companies with interests in
aerosol safety.
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